Aug. 4 at 7:29 AM
$CRDF all in all, in my view CRDF did take reasonable steps into onva developement, however key problem for NMS is that their exclusivity on molecule expires in 2030 so they won't have any monetary upside from approval of the drug and its sale (if I am not mistaken, so far NMS only received
$2M from CRDF when the agreement was signed while other milstones which would trigger additional payments are still not met).
So, it may stinks, but it is not fair that NMS do not receive basically nothing from the molecule they have invented and which have a reasonable chance of making it onto the market. So NMS should get some monetary upside over what current licence agreement gives them, but that should be of limited value having in mind the damage they have done to CRDF development efforts.
